Arginase 2, inducible-and endothelial-nitric-oxide synthase (iNOS and eNOS), indoleamine 2,3-dioxygenase (IDO) and TGF-beta, might impair immune functions in prostate cancer (PCA) patients. However, their expression was not comparatively analysed in PCA and benign prostatic hyperplasia (BPH). We evaluated the expression of these genes in PCA and BPH tissues. Seventy-six patients (42 BPH, 34 PCA) were enrolled. Arginase 2, eNOS and iNOS gene expression was similar in BPH and PCA tissues. TGF-beta1 gene expression was higher in BPH than in PCA tissues (p=0.035). IDO gene expression was more frequently detectable (p=0.00007) and quantitatively higher (p=0.00001) in PCA tissues than in BPH. IDO protein, expressed in endothelial cells from both BPH and PCA, was detectable in tumour cells in PCA showing evidence of high specific gene expression. In these patients, IDO gene expression correlated with kynurenine/tryptophan ratio in sera. Thus high expression of IDO gene is specifically detectable in PCA. 
Introduction
Prostate cancer (PCA) is the second leading cause of cancer-related death in men reaching 31.5% of annual newly diagnosed cancers (Edwards et al, 2005) . In order to improve the understanding of PCA induction and progression, a contemporary model should include a detailed analysis of mechanisms potentially inhibiting immune responsiveness to cancer.
A number of factors potentially impairing immune responses in PCA patients, such as arginase 2 (Bronte et al, 2005) , inducible nitric-oxyde synthase (iNOS) (Wang et al, 2003) , endothelial nitric-oxyde synthase (eNOS) (Tong and Li, 2004) and TGF-β (Adler et al, 1999) have been detected in surgical specimens. Interestingly, some of these immunosuppressive factors have been suggested to be able to inhibit anti-CD3 or PHA induced T cell proliferation (Bronte et al, 2005) . However, little is known about their comparative expression in PCA and benign prostatic hyperplasia (BPH). Thus, still open is the issue of the specificity of the expression of these genes as cancer signature.
Indoleamine 2,3-dioxygenase (IDO) eventually produced within tumors initiates the degradation of Tryptophan along the kynurenine pathway (Stone and Darlington, 2002) resulting in the production of immunosuppressive catabolites known to suppress T cell stimulation in vitro and to cause T cell apoptosis (Terness et al, 2002; Weber et al, 2006) . IDO expression has thus been proposed as a possible mechanism facilitating induction of immune tolerance towards cancer (Uyttenhove et al, 2003) . Interestingly, metabolites generated by IDO mediated tryptophan digestion have been shown to inhibit cytokine induced homeostatic T cell proliferation (Weber et al, 2006) . IDO expression has indeed been reported in PCA (Uyttenhove et al, 2003) . However, no comparison with BPH has been provided.
In the present study, we comparatively evaluated the expression of genes encoding potential immunosuppressive factors including IDO in PCA and BPH tissues.
Our results indicate that, among genes encoding factors known to affect immune response in PCA, IDO gene expression is characterized by the highest specificity for PCA tissues.
Materials and methods

Patients and samples
We investigated a consecutive series of 76 specimens from men diagnosed for BPH or PCA at the Department of Urology of the University Hospital of Basel (Switzerland) in 2007. BPH patients underwent conventional transurethral resection (TUR-P), while PCA patients underwent either palliative TUR-P or endoscopic extraperitoneal radical prostatectomy (EERP). Relevant clinical data were collected by reviewing patients' files.
Written informed consent was obtained from patients in accordance with the requirements of the Ethical Committee of Basel (EKBB, Ref.Nr. EK: 176/07).
Quantification of gene expression in prostatic tissues by quantitative Real-Time
PCR
Prostatic tissues resected during surgical procedures were screened for the presence of tumours by experienced pathologists at the moment of collection and immediately submerged in RNAlater (Ambion, Foster City, CA) and stored at -80°C until further processing. Total RNA was extracted by using RNeasy® Mini Kit protocol (Qiagen, Basel, Switzerland), treated by Deoxyribonuclease I (DNase I) (Invitrogen, Carlsbad, California), and reverse transcribed by using the Moloney Murine Leukemia Virus Reverse Transcriptase (M-MLV RT, Invitrogen, Carlsbad, California).
Quantitative Real-Time PCR was performed by a ABI prism™ 7700 sequence detection system, using the TaqMan® Universal PCR Master Mix, No AmpErase® UNG (both from Applied Biosystems, Forster City, CA).
The following primer sequences were derived from existing literature, as Probe FAM-CAG CAC GTG GAG CTG TAC CAG AAA TAC AGC-TAMRA   Arginase 2, iNOS, eNOS, IL-23p19 and IL-17 primers and probes were provided by Assays-on-Demand, Gene Expression Products (Applied Biosystems, Forster City, CA).
Specific gene expression was quantified by using the 2 -∆∆C T method (Livak and Schmittgen, 2001 ). Normalization of gene expression was performed using GAPDH as reference gene, and samples were considered positive for a ∆C T < 20 cycles. Data were expressed as ratio to reference samples represented by lipopolysaccharide (LPS) matured dendritic cells (mDC) or phytohemagglutinin (PHA) activated CD4+ T cells, as indicated in specific tests.
Immunohistochemistry
Indoleamine 2,3-dioxygenase (IDO) protein was detected on paraffin-embedded prostate section by a standard protocol (Bubendorf et al, 1996 ) using a mouse anti-IDO monoclonal antibody (AbD Serotec, Oxford, UK).
Measurement of tryptophan and kynurenine concentrations in serum from BPH and PCA patients
Measurement of tryptophan and kynurenine concentrations in sera from BPH and PCA patients was performed as previously described (Chiarugi et al, 2003) by highpressure liquid chromatography (HPLC) and fluorimetric detection. Sera were deproteinized by mixing it with an equal volume of 10% (w/v) trichloroacetic acid.
HPLC separation was obtained with a reverse-phase column (Spherisorb S5 ODS2, 25 cm) and a mobile phase (1 ml/min flow rate) composed of 5% acetonitrile, 100 mM phosphate buffer, pH 3.6, and 1 mM EDTA. Detection was performed with a PerkinElmer (Foster City, CA) model LC 240 fluorimeter (excitation and emission wavelengths were 313 and 420 nm, respectively).
Kynurenine was measured using HPLC and UV detection. Briefly, HPLC separation was obtained with a reverse-phase column (Spherisorb S5 ODS2, 10 cm) and a mobile phase (1 ml/min flow rate) composed of 2% acetonitrile, 0.1 mM ammonium acetate, and 100 mM acetic acid. Kynurenine was detected at 365 nm with a UV detector (Perkin-Elmer model LC 90).
Statistical Analysis
SPSS software (Version 14.0, SPSS Inc., Chicago, IL) was used for statistical analyses. Skewness and kurtosis parameters were used to test the "normality" of the populations of each group. Mann-Whitney non-parametric test was used to compare means for independent samples and Wilcoxon non-parametric test for paired samples was used on "non-normal" populations. The frequencies of specific gene expression in two groups were assessed by χ 2 evaluation. P-values lower than 0.05 were considered to be statistically significant.
Results
Clinical profiles of the patients
Average age of the patients enrolled in the study (n=76) and average Gleason score was 6.55 +/-1.26 (median: 7.00; range, 3-9). Average serum PSA value in BPH patients (n= 34) was 4.82 +/-5.84 ng/ml (median: 2.30 ng/ml; range, 0.30-26.00).
Expression of genes encoding immuno-suppressive enzymes from the L-Arginine metabolic pathway in PCA and BPH tissues
A number of reports suggest that enzymes involved in L-Arginine metabolism may favour cancer growth and development. In particular, arginases were suggested to play a potentially decisive role in PCA induction by enhancing cell proliferation (Keskinege et al, 2001) . Similarly, inducible NOS (iNOS) has been shown to be expressed in prostate cells (Wang et al, 2003) and endothelial NOS (eNOS) is known to protect prostate cancer cells from apoptosis (Tong and Li, 2004) . Finally, it has been suggested that arginase, possibly in synergy with NOSs may be able to inhibit T cell response to antigens, thereby favouring tumour escape from recognition by the immune system (Rodriguez et al, 2004 ).
We quantitatively analyzed arginase 2, iNOS and eNOS gene expression in our series of PCA and BPH tissues. As shown in figure 1, arginase 2 gene expression was Furthermore, no significant quantitative differences in eNOS gene expression between BPH and PCA positive cases were detectable (p=0.515).
Expression of genes encoding cytokines in PCA and BPH tissues
A number of cytokines have been suggested to be involved in PCA pathogenesis. In particular, IL-6 is known to be a mediator of PCA morbidity and disease activity, and may act as a cell growth factor and protect cancer cells from death.
In addition, it has been demonstrated that patients with metastatic PCA have increased IL-6 serum levels (Twillie et al, 1995) . We comparatively evaluated IL-6 gene expression in BPH and PCA tissues.
As shown in figure 2, IL-6 was expressed in 18/39 (46.2%) and in 26/32 (81.3%) of BPH and PCA specimens, respectively (χ 2 = 0.002). The extent of gene expression in positive cases was significantly higher in PCA as compared to BPH (p=0.00018),
indicating that IL-6 gene expression might indeed be of use in discriminating PCA from BPH tissues.
All three TGF-β isoforms, TGF-β1, -2 and -3 have been detected in prostate cells (reviewed in (Steiner, 1995) ). They share similar biological properties but present slightly different tissue distribution (Massague, 1990) . While TGF-β2 mRNA appears to be increased in BPH (Mori et al, 1990) , TGF-β1 mRNA levels have been suggested to be increased in PCA (Merz et al, 1994) . Additionally, patients with metastatic PCA displaying high levels of serum IL-6 have also been reported to present increased serum levels of TGF-β1 (Adler et al, 1999) . On the other hand, in normal prostate, TGF-β inhibits epithelial cell proliferation and stimulates apoptosis, thus acting in a tumour suppressor-like manner (Bello-DeOcampo and Tindall, 2003) .
In our series of samples, TGF-β1 gene was expressed in 32/39 (82.1%) and in 30/32 (93.8%) of BPH and PCA specimens, respectively (χ 2 = 0.14). However, unexpectedly, TGF-β1 gene expression in positive cases was quantitatively significantly lower in PCA as compared to BPH tissues (p=0.035).
The expansion of a newly characterized subset of CD4+ helper T cells specifically secreting IL-17 (Aggarwal and Gurney, 2002 ) is promoted by IL-23 which shares its p40 chain with IL-12 (Veldhoen et al, 2006) . The role played by these cytokines in tumour growth and immune responsiveness against tumours is debated. IL-23 has been reported to promote tumour incidence and growth (Langowski et al, 2006) , but also to induce immune enhancement and anti-tumour activity (Hao and Shan, 2006) .
No data are available so far regarding IL-23 expression and PCA. Also regarding IL-17, conflicting data have been reported on its capacity to promote or inhibit tumour growth "in vivo" (Aggarwal and Gurney, 2002; Numasaki et al, 2003) . Interestingly, IL-17 gene expression has been detected in prostate tissues (Steiner et al, 2003) .
IL-23A gene was only marginally expressed, in 7/32 (21.9%) and 6/25 (24%) of the BPH and PCA specimens, respectively (χ 2 = 0.85), under investigation ( Figure 2 ).
No significant quantitative differences were detectable between positive samples of the two groups (p=0.784).
Regarding IL-17 (figure 2), only 6/39 (15.4%) and 8/32 (25%) of BPH and PCA specimens, respectively (χ 2 = 0.31) were positive for specific gene expression, and no significant quantitative differences could be observed between positive PCA and BPH (p=0.343).
IDO expression in prostatic tissues
Tryptophan degradation by IDO has been proposed as a mechanism favouring tumour escape from immune response (Uyttenhove et al, 2003) .
We investigated IDO gene expression in our series of specimens. As shown in Prompted by these data we investigated IDO expression at the protein level by immunohistochemical analysis on paraffin embedded PCA and BPH tissues. To determine if local IDO expression in PCA could have a systemic impact, we measured the concentrations of tryptophan and of its IDO dependent metabolite kynurenine in sera from BPH (n=33) and PCA (n=34) patients, as described in materials and methods. Overall, no significant differences (p=0.111) were detected in kynurenine/tryptophan ratios in sera from PCA as compared to BPH patients (data not shown). However, in the subgroup of PCA specimens displaying a high level of IDO gene expression, a significant correlation between the expression of this gene and serum kynurenine/tryptophan ratios in sera (P=0.0045, R 2 =0.8406) were observed, thus suggesting an increased metabolism of the target aminoacid (figure 3 panel 3).
In these patients, a highly significant correlation between IDO and TGF-β1 gene expression was also detectable (table 2) . In contrast IDO gene expression in PCA tissues did not correlate with Gleason score, pT stage or PSA levels.
Discussion
Neoplastic cells are detectable with high frequency in prostates from aged males.
However, only in a minority of cases outgrowth of clinically relevant cancers can be observed. Mechanisms governing this transition are unclear, but it is tempting to speculate that defective tumour specific immune responsiveness could be involved.
Indeed, a number of factors have been suggested to be able to impair the functions of the immune system in PCA. However, the expression of genes encoding these factors in PCA and in BPH has not been comparatively addressed so far.
In this study, we show that PCA and BPH specimens display a similar expression of several genes encoding potentially immunosuppressive factors, such Arginase 2, iNOS and eNOS. Conflicting data have been reported regarding the capacity of IL-23 and IL-17 to favour or inhibit cancer growth (Benchetrit et al, 2002; Langowski et al, 2006; Numasaki et al, 2003) . We found that the overall expression of the genes encoding these factors is weak in prostate specimens, but nevertheless similar in BPH and PCA (Steiner et al, 2003) . Interestingly, a significant decrease in TGF-β1 gene expression in PCA as compared to BPH was concomitantly detected.
Although the specimens under investigation were carefully screened for the presence of tumours by experienced pathologists at the moment of tissue collection, we cannot formally exclude that they did not actually contain tumour cells. Remarkably, however, the expression of the gene encoding IL-6, previously indicated as a possible mediator of prostate cancer morbidity (Twillie et al, 1995) , was found to be highly significantly enhanced in PCA as compared to BPH tissues under investigation. These data help validating the integrity of our technical approach. We found that although IDO gene expression is also detectable in BPH specimens, it is strongly enhanced in a sizeable percentage of PCA specimens. Notably, overall IDO gene expression is significantly correlated with the expression of the gene encoding AMACR A, a candidate biomarker for PCA (Xu et al, 2000) . Most interestingly, in the subgroup of PCA patients whose tumours express high levels of IDO gene, a significant increase of the kynurenine/tryptophan ratio is detectable in the sera. These data suggest that the impact of IDO gene expression could extend beyond tumour microenvironment and result in systemic effects.
Interestingly, in our study, IDO protein was frequently expressed by endothelial cells rather than by tumour cells in BPH and PCA tissues expressing low level of IDO gene. Notably, IDO has been shown to be expressed at the protein level mainly by vascular endothelial cells in term placenta (Ligam et al, 2005) and in renal cell carcinoma (Riesenberg et al, 2007) . Furthermore, inhibition of IDO activity is known to improve the ability of HUVEC cells to stimulate allogenic T cell responses, and HUVEC cells transfected with the IDO gene induce anergy in allospecific T cells (Beutelspacher et al, 2006) .
However, in PCA specimens of our series where high levels of IDO gene expression were observed, IDO protein was also focally detectable in tumour cells.
Remarkably, prostate cancer cells expressing IDO protein were often located in areas of inflammation and atrophic glands and ducts were found to be positive for IDO specific staining in PCA.
Taken together, our findings indicate that while Arginase 2, eNOS and iNOS are similarly expressed in both BPH and PCA, high IDO gene expression is typically detectable only in a subgroup of PCA, but not in BPH. In patients bearing these tumors a high kynurenine/tryptophan ratio can also be observed in sera. a. Kynurenine/Tryptophan ratios in sera b. Gene expression in tissues
